Abcellera Biologics Inc
$ 5.24
-0.57%
12 Jun - close price
- Market Cap 1,600,167,000 USD
- Current Price $ 5.24
- High / Low $ 5.41 / 5.13
- Stock P/E N/A
- Book Value 3.09
- EPS -0.48
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.15 %
- 52 Week High 6.79
- 52 Week Low 2.75
About
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$10.43
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-24 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.14 | -0.03 | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.16 | -0.1 | -0.11 |
| Estimated EPS | -0.2 | -0.144 | -0.16 | -0.16 | -0.14 | -0.1471 | -0.13 | -0.14 | -0.16 | -0.12 | -0.13 | -0.12 |
| Surprise | 0.06 | 0.114 | -0.03 | 0.04 | -0.01 | 0.0271 | -0.04 | 0.01 | 0.02 | -0.04 | 0.03 | 0.01 |
| Surprise Percentage | 30% | 79.1667% | -18.75% | 25% | -7.1429% | 18.4228% | -30.7692% | 7.1429% | 12.5% | -33.3333% | 23.0769% | 8.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABCL
2026-06-12 18:39:45
AbCellera Biologics recently appointed Victor Sandor, an experienced oncology drug developer, to its Board of Directors. This move is seen as potentially strengthening investor confidence in AbCellera's clinical and regulatory capabilities, especially as the company transitions from a discovery platform to a clinical-stage biotech. Sandor's expertise is expected to complement AbCellera's efforts to advance assets like ABCL635 amidst ongoing net losses and significant R&D investment.
2026-06-12 18:38:49
At its Annual Meeting, AbCellera Biologics shareholders approved the election of John S. Montalbano and Stephen R. Quake as Class III directors for three-year terms. They also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and passed a non-binding advisory vote to approve the compensation of the company's named executive officers.
2026-06-12 18:38:49
AbCellera Biologics (ABCL) has appointed Dr. Victor Sandor, an experienced oncology drug developer, to its Board of Directors. This move is seen as potentially strengthening investor confidence in AbCellera's transition from a discovery platform to a clinical-stage biotech, particularly concerning its oncology programs like ABCL635. While Sandor's appointment doesn't change clinical timelines, his regulatory and late-stage oncology expertise could help validate the company's development ambitions amidst its current net losses and significant R&D investments.
2026-06-12 16:39:46
AbCellera Biologics Inc. (NASDAQ: ABCL) shareholders approved all proposals at their annual meeting on June 11, 2026. This included re-electing Class III directors John S. Montalbano and Stephen R. Quake, ratifying Ernst & Young LLP as the independent auditor for 2026, and approving the executive compensation ("Say-on-Pay") on a non-binding advisory basis. The meeting saw active participation, with over 305 million common shares outstanding and eligible to vote.
2026-06-12 16:38:49
AbCellera Biologics Inc. director John S. Montalbano was granted 111,701 share options with an exercise price of $5.27 per share. These options will vest and become exercisable at the 2027 Annual General Meeting, provided he continues his service to the company. Following this grant, Montalbano now holds a total of 1,141,544 share options in AbCellera.
2026-06-12 16:38:49
AbCellera Biologics Inc. director Stephen Quake was granted 111,701 share options, allowing him to purchase common shares at an exercise price of $5.27 per share. This award increases his total outstanding options to 306,633 common shares. The options are compensation-related and will vest at the company's 2027 Annual General Meeting, provided Quake continues his service to the company.
